HERNIAMESH acquired by VITREX MEDICAL GROUP
Context
Vitrex Medical Group (VMG) has finalized the acquisition of a majority stake in Herniamesh, an operation designed to fundamentally accelerate the group's transformation into a global leader in surgical technology. The strategic rationale for this transaction centers on a "portfolio-synergy" play, merging the target's industry-leading technical operational depth in surgical meshes with the group’s extensive distribution network and established suture division (CHIRMAX). This fusion effectively creates a specialized powerhouse in the European medtech arena, providing the organization with the scientific talent and technological hardware required to address the increasing complexity of soft tissue repair and urogynecological procedures.
HERNIAMESH, which reported an EBITDA margin of in 2026, is valued in this transaction at an EV/EBITDA multiple of , a level to compare with the average currently observed in the Healthcare & Pharma sector (15.6x).
-> Deep-dive in Healthcare & Pharma market trends
Target
erniamesh s.r.l. operates as a premier technology-enabled organization dedicated to the engineering and fabrication of advanced surgical solutions for the treatment of hernias, female incontinence, and pelvic floor disorders. The entity’s business model is centered on a proprietary innovation framework, utilizing clinical know-how established by renowned surgical practitioners to develop specialized medical materials. Its value proposition is anchored in technical operational depth, providing a high-fidelity portfolio of surgical meshes and biological materials that facilitate minimally invasive procedures and improve patient outcomes. Strategically, the firm focuses on the deployment of standardized, high-quality "Made in Italy" devices across a global commercial network spanning North America, Asia, and Latin America. By maintaining a specialized focus on technical reliability and surgical precision, the organization ensures a vital role in the structural advancement of soft tissue repair standards.
Ent. Value
Equity Value
Multiples
EV / Revenue
EV / EBITDA
EV / EBIT
Historical Financials (EUR)
Similar deals in Life Sciences
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 06/2026 | BRIDGEPOINT | OBAGI MEDICAL | UNITED STATES | Generics / Labs |
| 05/2026 | STRYKER | AMPLITUDE VASCULAR SYSTEMS | UNITED STATES | Medical Devices |
| 04/2026 | UCB | NEURONA THERAPEUTICS | UNITED STATES | R&D Biotech |
| 04/2026 | OURY MEDICAL | CÉFIMÉCA | FRANCE | Implants & Prosthetics |
| 04/2026 | ASTORG | THERMO FISHER MICROBIOLOGY | UNITED STATES | Diagnostic Equipment |
| 04/2026 | RANTUM CAPITAL | TONTARRA MEDIZINTECHNIK | GERMANY | Medical Devices |
| 04/2026 | DEVYSER DIAGNOSTICS | CYBERGENE | SWEDEN | Diagnostic Equipment |
| 04/2026 | Gilead Sciences | Arcellx | UNITED STATES | R&D Biotech |
| 04/2026 | REVENIO GROUP CORPORATION | VISIONIX INTERNATIONAL | FRANCE | Diagnostic Equipment |
| 04/2026 | FINE FOODS & PHARMACEUTICALS | SOFAR | ITALY | CDMO |
REFERENCES
Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of HERNIAMESH by VITREX MEDICAL GROUP are reserved for mynth community members. Register for free to unlock full data.
Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.
Target: herniamesh
Acquirer: vitrex medical group